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Abstract
Background: In a world of finite research funding, efforts to prioritize future research topics are
increasingly necessary.
Objective: The aim of this study was to identify and prioritize the direction of future research in the
broad area of low-calorie sweetener (LCS) intake and potentially related health outcomes by using
a novel method that incorporates evidence mapping in the Agency for Healthcare Research and
Quality’s Future Research Needs (FRN) process.
Methods: A diverse expert stakeholder panel was convened and engaged to identify research
gaps and prioritize future research needs. An independent research team hosted a number of
interactive webinars and elicited feedback through surveys and individual interviews with the
stakeholder panel, which included policymakers, lay audience members, health providers, a
research funder, individuals with food industry experience, and researchers of several different
specialties.
Results: The stakeholder panel generated and ranked a list of 18 FRN questions across 5 broad
research areas. Overall, stakeholder panel members unanimously agreed that the research
questions that will have the largest public health impact are those that address outcomes related
to body weight, appetite, and dietary intake. Although the LCSs included in this FRN project have
all been Generally Recognized as Safe by the FDA or approved as food additives, the recurrent
concerns and confusions with regard to the “safety” of LCSs by consumers underscore the
importance of communicating the science to the general public.
Conclusion: Our project provides evidence that engaging a diverse expert stakeholder panel is an
effective method of translating gaps in nutrition research into prioritized areas of future
research. Curr Dev Nutr 2017;1:e000547.
Introduction
A structured approach for examining the results of systematic reviews and prioritizing re-
search gaps from systematic reviews, namely the Future Research Needs (FRN) process,
has been developed by the Agency for Healthcare Research andQuality (AHRQ) (1). The cur-
rent AHRQ FRN process begins by identifying a list of evidence gaps from a systematic
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review. Next, the systematic review team works with a stakeholder
panel to first elaborate on and then consolidate the evidence gaps.
Finally, the research questions are prioritized by the stakeholders
according to a set of criteria focused on the potential value of the re-
search. Since 2010, the AHRQ has supported studies that develop
and prioritize the future research needed by decisionmakers in a va-
riety of health care content areas (2). However, none to date are re-
lated to nutrition topics. Furthermore, nutrition-related systematic
reviews only comprise ;8% of all systematic reviews in the Co-
chrane Database of Systematic Reviews and, among these, approxi-
mately half focus on nutritional supplementation or supplements
(3). Due to the anticipated need to consider broader research ques-
tions for public health nutrition, we previously modified the ARHQ’s
FRN approach by integrating an evidence-mapping process (4). Ev-
idence mapping is an emerging evidence synthesis method for de-
scribing the volume and characteristics of research in a broad
field. This method can be used to identify areas, known as research
gaps, in which there is a lack of evidence and further studies may be
needed, as well as research-dense areas in which systematic reviews
could be pursued. With the use of evidence mapping, one can
quickly become informed and identify research gaps without having
to conduct a comprehensive systematic review.
The aim of this article was to summarize the processes and re-
sults of this new FRN approach by using the published literature
on low-calorie sweeteners (LCSs) and selected health outcomes as
an example of its application. As concerns increase with regard to
a link between added sugars and obesity risk (5, 6), there is in-
creasing interest in LCSs (artificial sweeteners, non-nutritive
sweeteners, or high-intensive sweeteners) as a tool to help reduce
excess energy intake and body weight. With LCSs being widely
used in foods and beverages for decades, the questions on their
role in health and whether there are adverse health risks associ-
ated with use of LCSs over the course of many years remain unset-
tled. In the United States, there are 2 regulatory routes allowed by
the FDA for LCSs permitted for use in foods: either as “food addi-
tives” or as ingredients Generally Recognized as Safe (GRAS); both
require rigorous toxicologic review (7, 8). For a food additive, the
FDA reviews animal and human studies designed to identify pos-
sible toxic effects in any major body system, then evaluates it
under conditions of intended use and expected exposure to deter-
mine an acceptable daily intake level (9–11) considered to be safe
over a lifetime. Currently, aspartame, saccharin, acesulfame potas-
sium, sucralose, neotame, and advantame are approved food addi-
tives; and some stevia-based sweeteners (i.e., high-purity stevio
glycosides such as stevioside and Rebaudioside A isolated from
the leaves of Stevia rebaudiana Bertoni) (12) and Luo Han Guo
(also known as swingle fruit or monk fruit) extracts are GRAS
(8, 10). Other LCSs are outside the scope of this project.
Methods
The initial scope of work was developed by the sponsor of this pro-
ject [International Life Sciences Institute (ILSI) North American
branch] in a request-for-proposals. Aside from providing initial feed-
back on our funded research proposal and identifying potential
stakeholders, the sponsor was not involved in the later refinement
of the scope of work, evidence mapping, or FRN processes. The fol-
lowing 5 areas of research with regard to the potential health effects
of LCSs were all considered and included: 1) energy sensing by the
brain, 2) gut hormones that may influence energy homeostasis, 3) sa-
tiety and taste preference, 4) eating behavior, and 5) bodyweight and
composition. The project consisted of the research team and the ex-
pert stakeholder panel. The panel was tasked with overseeing and
advising the development of the search strategy, study inclusion
and exclusion criteria, and prioritization of FRN research questions.
The research team was in charge of data screening, abstraction,
analysis, and visualization.
Recruitment of the expert stakeholder panel
The research team collaborated with the project sponsor, the Tech-
nical Committee on Low Calorie Sweeteners at the ILSI North
American branch, to identify potential stakeholder panel members.
We used the “7 Ps of Stakeholder Engagement” approach to es-
tablish and organize our panel. This framework highlights 7
stakeholder groups to engage in developing and refining study
protocols. The 7 groups are as follows: patients, providers, re-
searchers, policymakers, product makers, payers, and purchasers
(13). In our study, panel members were selected to provide a vari-
ety of perspectives and broad expertise with regard to LCSs,
evidence-based decision making, and health research. Potential
project stakeholders were sorted into the following categories:
lay audience, policymakers, health providers (physicians, dieti-
tians), research funders, researchers (with expertise in epidemiol-
ogy, intervention studies, statistics, and taste), and individuals
with food industry product-development experience. Our goal
was to recruit individuals in each of these categories.
Potential stakeholders were first approached via e-mail invi-
tation. The research coordinator and principal investigator dis-
cussed the project in more detail with those who were interested
and answered any initial questions through e-mail or phone
conversations. Individuals who responded to the invitation
with interest were required to submit a curriculum vitae and
disclose any potential conflicts of interest; they were asked to
disclose financial conflicts of interest .$10,000, as well as any
other potential conflicts, for the research team to review before
accepting their participation on the panel. Due to their unique
expertise, individuals with conflicts of interest were not auto-
matically excluded, but all conflicts were first reviewed by the
research team and then shared with ILSI for discussion. ILSI
and the research team then reached a consensus about each in-
dividual’s qualification. The purpose of this vetting process was
to screen out any individuals with clear financial interests in the
results of this project and to promote transparency in the re-
porting of our results. To minimize the potential for bias result-
ing from conflicts of interest, our panelists who had retired from
the industry sector were considered “nonvoters” who could not
cast votes on the final prioritization of FRN topics, although
they still provided their insights and expertise throughout the
project. At the beginning of the project (August 2014), 25 poten-
tial stakeholder candidates were contacted. Of these, 7 did not
respond, 1 declined to participate, and 1 was excluded due to a
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major financial conflict of interest. Thus, 16 stakeholders were
recruited to form the panel. The final panel consisted of 15 indi-
viduals. A list of the panel members is presented in Table 1.
Evidence mapping
To build a literature database for evidence mapping, the research
team developed a search strategy to capture all relevant research ar-
ticles in the defined scope of work, as described above. Research ar-
ticles were restricted to randomized or nonrandomized controlled
clinical trials or prospective cohort studies involving humans. The
search strategy was reviewed, and additional search terms were
added by the stakeholder panel. Articles were screened in multiple
rounds on the basis of our inclusion and exclusion criteria, which
were also developed with the help of the panel. Each article was
screened by $2 investigators, and discrepancies were discussed
and resolved. The full texts of relevant articles were abstracted
and an evidence-map database was developed, including informa-
tion on study design, demographic characteristics, and health status
of the participant population; health outcomes of interest; LCSs; and
comparisons used in the experiment and findings. The final LCS
evidence-map database included 225 studies and was uploaded
onto SRDR (Brown University Evidence-based Practice Center),
an open public data repository (14). A synthesized summary report
of the quantity and characteristics of the published literature in the
evidence-map database was presented to the stakeholder panel dur-
ing a round-table in-person meeting to augment and guide discus-
sions of current gaps in the published literature. The process of
evidence mapping and the results are reported elsewhere (15). It
is important to note that, although literature gaps may exist, both
the importance and feasibility of further research involve judgment
of various expert stakeholders, whichwas the objective of this panel.
Stakeholder panel engagement
Published literature search. The stakeholder panel was engaged
throughout the project. Figure 1 shows a timeline of the overall
project, highlighting major project activities. In general, the re-
search team sent out biweekly e-mails and hosted monthly webi-
nars. During the webinars, the research team presented the status
of the project. The initial webinar served as an introduction to the
project, including evidence-mapping methods and how the find-
ings would be used to inform the FRN project. Subsequent
webinars were used to present preliminary findings of our pub-
lished literature search and abstraction, as well as to refine inclu-
sion and exclusion criteria and add additional search terms.
Stakeholders were encouraged to ask questions and make com-
ments, and detailed minutes were kept. Minutes as well as presen-
tation slides were shared with the panel after each webinar and a
web page was customized for the project to store and share pro-
ject documents, as well as to facilitate further discussion. Impor-
tant project decisions, including study inclusion or exclusion
criteria and other search strategy details discussed during project
webinars and on the project website, were finalized by using
stakeholder feedback collected through a series of online surveys
and follow-up e-mails. Specifically, surveys used a series of multi-
ple choice questions to quantify the number of panel members
that agreed and disagreed with proposed changes, as well as
open-ended questions for panel members to provide additional
explanation and suggestions.
Development of FRN questions. In December 2014, the research
team convened a 1-d, in-person meeting with the stakeholder
panel. At this meeting, the research team presented a draft of
the Evidence Mapping Summary Analysis report, which the panel
was sent a few days before to review. The summary report was or-
ganized into sections by various health outcome categories and
provided detailed summaries of the frequencies of various end-
points and other study characteristics in the published literature.
These findings were used to spur, as well as to inform with de-
tailed quantitative information, discussion about potential re-
search gaps and future research needs. Stakeholders took turns
facilitating discussions on different sections of the report, assigned
at the start of the meeting, and conversations were recorded in or-
der to improve the quality of the detailed meeting minutes. The
overall goal of the in-person meeting was to facilitate discussion
and to document as many different perspectives on research
gaps and priorities as possible for later use in refining and priori-
tizing research questions.
For that reason, citing scientific references or using the Evi-
dence Mapping Summary Analysis report and database were en-
couraged but not required to support the statements or opinions
raised by the stakeholder panel. At the conclusion of each discus-
sion, the panel was encouraged to translate the list of identified
gaps in the literature into a preliminary list of research questions.
A final webinar was scheduled after this meeting to revise the
list of questions and to ensure that they were fully reflective of the
meeting discussions. The final step in refining the list of FRN
questions was the administration of a final online survey that
gave stakeholders the opportunity to make edits. Panel members
were allowed to suggest wording changes, the combination or
elimination of certain questions, and to add any questions they
felt were missing. E-mails were used to share survey results and
resulting project decisions with the panel.
Semistructured interviews
In the period between the final webinar and the survey to refine the
list of research questions, the research coordinator and principal in-
vestigator conducted semistructured interviews with individual
TABLE 1 Initial FRN stakeholder panel1
Stakeholder group Number of stakeholders in group
Lay audience 2
Policymaker 32
Health provider 3
Research funder 1
Product maker (nonvoters) 2
Researcher (intervention) 2
Researcher (epidemiology) 1
Researcher (statistics) 1
Researcher (taste) 1
1FRN, Future Research Needs.
2The final stakeholder panel included 15 individuals. One policymaker dropped
out for personal reasons.
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stakeholders. Interviews were recorded and detailed notes were
taken from each interview. The purpose of these interviews was
to give all stakeholders the opportunity to share their thoughts on
our question list, as well as on the more pressing areas for future in-
vestigation. Our discussions with each stakeholder started with a
simple question: If you had unlimited funding, what research would
you do with LCSs? Their answers then led the rest of the conversa-
tion about research prioritizations and the state of the science. At
the start of each interview, stakeholders were reminded of the
area of expertise they were recruited to represent to encourage
them to viewour discussion from that perspective. For example, pol-
icymakers were asked to consider and discuss the questions with re-
gard to their potential impact on public health policy. Fourteen of the
15 panel members completed interviews. One stakeholder, a health
provider, could not be interviewed due to scheduling conflicts.
Final FRN question prioritization
Once the list of questions was finalized, the research team designed
one final online survey to prioritize research questions with the use
of a framework following the Effective Health Care Program Selec-
tion Criteria (16), slightly modified for application in the public
health nutrition field. Stakeholders were presented with an updated
list of research questions, which reflected suggestions and revisions
collected from the final webinar, question refinement survey, and
semistructured interviews. They were asked not only to rate ques-
tion priority but also to suggest a categorization scheme for the
questions and to indicate any final wording changes they wanted to
make. When prioritizing the research questions, stakeholders were
asked to rate each research question on a scale of 1 to 5, from lowest
to highest, for 4 separate dimensions: importance, desirability, feasibil-
ity, and potential impact. The final 18 questionswere shown to respon-
dents in randomorder to avoid question-order bias. The average of the
4 dimension scores each question receivedwas used as the overall pri-
ority score, and research questions were ranked in order by average
overall priority score for all respondents (Table 2). The final deliver-
able of the FRNprojectwas a list of FRN research questions, identified
and prioritized by the members of the stakeholder panel.
Results
Of the 16 stakeholders initially recruited to the panel, 1 dropped out
during the course of the project due to personal reasons. A total of 13
members across 7 stakeholder groups participated in $3 of 4 webi-
nars. The average response rate for the online surveys was 85%. The
stakeholder panel remained engaged throughout the project and
was frequently encouraged to contact the research team at any
time with questions or concerns.
Research gaps identified by published systematic reviews
The 2015–2020 Dietary Guidelines for Americans suggest a reduc-
tion in “added sugars consumption to ,10% of calories per day”
FIGURE 1 Timeline of the FRN project. FRN, Future Research Needs.
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TABLE 2 Ranking of FRN questions by priority1
Rank
Score,
mean 6 SD Question category Questions
1 4.4 6 0.8 Physiologic (or clinical) impacts Q1. Do LCSs aid weight loss and/or weight
maintenance?
2 4.2 6 0.9 Behavioral impacts Q2. Does LCS consumption modify appetite (hunger,
fullness, desire to eat 6 prospective consumption)
and/or total energy intake and, if so, how?
3 3.9 6 0.9 Mechanistic questions Q3. Does the use of LCSs affect insulin secretion,
carbohydrate metabolism, or the gut microbiota and
its function? If so, where is this happening (cognition,
sweet receptors on tongue, receptors in
gastrointestional tract, etc.) and does it have any
physiologic consequences on health?
4 3.9 6 1.0 Physiologic (or clinical) impacts Q4. Are there potential long-term health risks (obesity,
diabetes, cancer, CVD, etc.) of LCS consumption in
humans? Are certain population groups (diabetics,
children, pregnant women, those with genetic disease)
more susceptible to the potential health risk(s)?
5 3.8 6 0.9 Mechanistic questions Q5. Is LCS sweetness perceived by the brain as energy
in the same way as other sweeteners? Do those who
are overweight or obese sense LCSs differently than
normal-weight people?
5 3.8 6 1.2 Physiologic (or clinical) impacts Q6. Are there impacts of LCS consumption during
pregnancy on the fetus?
5 3.8 6 1.1 Impact on dietary intake Q7. Do LCSs differentially affect long-term food intake,
eating frequency, and portion sizes in children,
adolescents, and adults? Is there an impact on dietary
quality and adherence to recommended dietary
patterns?
6 3.6 6 0.8 Physiologic (or clinical) impacts Q8. In individuals with diabetes and prediabetes, does
chronic consumption of LCSs have an impact on
glycemic control, alter glucose transport, or invoke a
cephalic phase response?
7 3.6 6 1.0 Impact on dietary intake Q9. Does LCS consumption affect consumption of
other sweeteners or sugars or total carbohydrate
intake? Is the effect different than that from
consumption of nutritive sweeteners?
8 3.6 6 1.0 Mechanistic questions Q10. Do LCSs affect energy metabolism and fat
storage?
9 3.5 6 1.0 Cross-cutting methodology-related, policy- or
evidence-based decision-making questions
Q11. Should study findings be evaluated for each LCS
individually or collectively? To which health outcome(s)
are the findings from individual LCSs generalizable to
the class of ingredients?
10 3.5 6 1.1 Cross-cutting methodology-related, policy- or
evidence-based decision-making questions
Q12. Is LCS intake accurately estimated in current
dietary assessment tools?
11 3.2 6 0.7 Behavioral impacts Q13. Are there interactions between the combination
of fat substitutes and sweetener substitutes on appetite
(hunger, fullness, desire to eat 6 prospective
consumption) and/or total energy intake?
12 3.1 6 1.0 Cross-cutting methodology-related, policy- or
evidence-based decision-making questions
Q14. Is there any variation in how LCSs affect those of
different ages, races, and ethnicities?
13 3.1 6 0.9 Mechanistic questions Q15. Do individuals with different dietary patterns (high
protein vs. high carbohydrate, etc.) affect the
metabolism of LCSs differently and, if so, how?
14 3.0 6 1.0 Cross-cutting methodology-related, policy- or
evidence-based decision-making questions
Q16. How do we design a system or methodology to
address the differences in existing LCS compounds vs.
compounds that will be emerging down the road?
15 3.0 6 1.0 Physiologic (or clinical) impacts Q17. Do the effects of LCS consumption on body
weight differ by sex? If so, what are the sex-specific
mechanisms of the impact of LCS consumption on
body weight?
16 2.7 6 1.0 Cross-cutting methodology-related, policy- or
evidence-based decision-making questions
Q18. Has there been a gradual increase in the overall
sweetness in our diet?
1CVD, cardiovascular disease; FRN, Future Research Needs; LCS, low-calorie sweetener; Q, question.
CURRENT DEVELOPMENTS IN NUTRITION
Research priorities for low-calorie sweeteners 5
to help the public achieve a healthy eating pattern (17). The Dietary
Guidelines for Americans provide a list of replacement options in-
cluding LCSs and conclude that these LCSs are safe for the general
population on the basis of available scientific evidence. The guide-
lines also stated that “replacing added sugars with LCSs may reduce
calorie intake in the short term, yet questions remain about their
effectiveness as a long-term weight management strategy” (17).
We identified 4 systematic reviews examining the association
between intakes of LCSs and body weight or risk of obesity (18–
21). Three of these recommended that future LCS studies focus
on long-term interventions in high-quality trial settings. One of
these systematic reviews by Rogers et al. (21) suggested switching
the research focus to how to best utilize LCSs to achieve specific
public health goals.
In-person meeting and research question generation
During the in-person meeting, the stakeholder panel generated a list
of 39 preliminary research questions. Although these questions were
mostly associated with specific outcome groups (e.g., appetite and/
or satiety), there were also a number of cross-cutting questions gen-
erated that addressed other topics; examples include how accurately
current dietary assessment tools capture LCS intake andwhether re-
search specific to one LCS could be generalizable to the entire class
of LCSs. Through the final webinar with the stakeholder panel, this
initial list was then narrowed down to 26 questions by merging sim-
ilar ideas into more targeted questions.
Semistructured interviews
Semistructured interviews were used in May and June of 2015, be-
fore the final ranking of questions, to collect detailed responses with
regard to how different perspectives (i.e., researcher compared with
policymaker) affect future research prioritization. Several themes
emerged, including the need for more randomized controlled trials,
discrepancies between the public perception of LCSs and that of sci-
entists, and the importance of certain questions over others from
a public health significance perspective.
The potential impact of LCSs on energy intake and research to
better capture current intakes of LCSs was generally identified as
the most pressing research topic in the interviews. There was also
interest in the benefits and risks of substituting sugar with LCSs in
the diets of individuals with diabetes, particularly from our dieti-
tians. Several panel members were interested in efforts to identify
a common measurement and endpoint for all LCSs so that they
could be referred to collectively as a class of ingredients, despite
their unique chemical structures, physical and chemical proper-
ties, and taste profiles. It was also discussed that weight outcomes
were important due to the continued controversy surrounding the
role of LCSs in weight management. Specifically, it was noted that
proposed mechanisms linking LCSs to increased energy intake,
such as the idea that LCSs may interfere with the body’s recogni-
tion of calories in response to sweetness or that LCSs may alter the
perception of or preference for sweetness, needed to be rigorously
tested in humans (20, 22). In addition, our lay consumer stake-
holder was most interested in the role of LCSs in weight loss, fee-
ling that LCSs are used in many diet products and marketed as
products to assist in weight management. Overall, although
researcher stakeholders had a variety of different priorities,
most agreed that the potential impact of LCSs on energy intake
was the most important for public health impact.
Final question prioritization
Last, the research team administered an online survey to the stake-
holder panel (100% response rate) to collect feedback on the list of
26 questions and to give them a final opportunity to propose any
questions that could be missing from the list. Again, the votes cast
by stakeholders with previous food industry experience were not
counted in the calculation of priority scores. The results of the sur-
vey helped the team group andmerge similar questions to form a list
of 18 research questions (Table 2), categorize each into 1 of 5 groups,
and rank the questions on the basis of the Effective Health Care Pro-
gram Selection Criteria (i.e., importance, desirability, feasibility, and
potential impact) (16), with slight modifications for application to
the field of public health nutrition. The 5 groups were as follows:
“physiological (or clinical) impacts,” “behavioral impacts,” “mecha-
nistic questions,” “impact on dietary intake,” and “crosscutting
methodology-related questions, policy or evidence-based decision-
making.” These 5 conceptual groups show how the 18 FRN ques-
tions are linked to one another in a larger framework and may
help in the design of future studies (Figure 2).
Discussion
In 2012, a joint scientific statement from the American Heart Asso-
ciation and the American Diabetes Association concluded that, al-
though they considered limiting added sugars in beverages and
food to be an important strategy for supporting optimal nutrition
and healthy weight, there were insufficient data to determine if
the use of LCSs to displace caloric sweeteners reduced the intake
of total added sugars or carbohydrates, or if they modified appetite,
energy balance, body weight, or cardiometabolic risk factors (23).
More recently, the Scientific Report of the 2015 Dietary Guidelines
Advisory Committee reviewed the evidence from 3 systematic re-
views on the relation between LCS intake and measures of body
weight and obesity in adults and children. It concluded that mod-
erate evidence supported replacing sugar-containing beverages
with beverages containing LCSs to reduce calorie intake, body
weight, and adiposity (24). However, studies of the effects of
LCSs on other health indicators, such as cardiometabolic risk
factors, behavioral impact, or dietary intake, were not reviewed
in the report. Similarly, a 2015 systematic review identified a lim-
ited number of studies examining the effects of sugar-sweetened
beverages with other beverage alternatives (i.e., water, LCS-
sweetened beverages, coffee, tea, 100% fruit juices, and milk)
on long-term (defined as$4 mo) health outcomes (i.e., type 2 di-
abetes, stroke, and cardiometabolic risk factors) in both children
and adults. Again, although the authors concluded that beverage
alternatives may be beneficial for long-term body-weight man-
agement, the evidence was inadequate to draw any firm conclu-
sions on other health outcomes (25).
This FRN project aimed to use a novel approach to identify and
prioritize the direction of future research in the broad research
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area of LCS intake and its potentially related health outcomes. Our
team previously carried out a similar project with a different
group of stakeholders and identified several challenges highlight-
ing the importance of engaging a diverse stakeholder panel in the
process (4). This article details how we engaged a multidisciplin-
ary stakeholder panel in elaborating and prioritizing FRN ques-
tions, because this methodology shows promise for use in future
evidence-based nutrition research decision making. Furthermore,
this FRN project showed how evidence-mapping results could
be translated into a list of prioritized research questions that
are more immediately usable by policymakers, funders, and
researchers.
Discussions on FRN questions from the semistructured
interviews
Our stakeholder panel members unanimously agreed that the re-
search questions that will have the largest public health impact
are those that address body weight, appetite, and dietary intake.
When asked what research project they would do if they had no
funding limitations, most reported studies with these outcomes.
Many indicated that these are the types of questions that will drive
health policy and were especially interested in the role of LCSs as
either a barrier or facilitator to meeting the federal dietary guide-
lines for the general public. The question of whether chronic LCS
intake has any impact on sweet preference was also deemed to be
important to understanding potential impacts on dietary intake. In
addition, a few panel members brought up the importance of LCS
studies specifically in populations with type 2 diabetes, because
this is a group likely to benefit the most from use of these products.
Some published systematic reviews also recommend more research
on the consumption of LCSs and their association with health risks
related to excess body weight (18, 26, 27), as well as on overall die-
tary patterns (20). Some mechanistic questions of interest were
around the sensing of LCSs at oral and gastrointestinal receptors,
as well as their potential impact on gut microbiota and peptide sig-
naling. It was generally recognized that the mechanistic “how”
questions are important, but that it was more pressing to conduct
public health population research on LCSs and these health
outcomes.
Question 4 (Table 2) raised concerns about the long-term
health risks of LCSs. An issue that came up in several interviews
was the distinction between “safety” and “health risks” and the
perception among some of the public that LCSs are “unsafe.” Be-
cause the scope of this FRN project included only human studies
and the stakeholder panel did not include a toxicologist, the panel
was not adequately equipped to assess the need for further safety
research. However, our panel members thought it was important
to clarify that the LCSs included in this FRN project have all
been either confirmed as safe for use as a sweetener (food addi-
tive) by direct review of research or accepted as GRAS. The panel
members knew of no evidence from human studies that these
LCSs are unsafe and felt that the public’s concern about the “ar-
tificial” nature of LCSs was the source of much of the confusion
with regard to the safety of LCSs. It was further noted that con-
sumers receive a lot of mixed messages from the media and var-
ious nutrition information about “diet” products containing
FIGURE 2 Conceptual framework of FRN questions. CNS, central nervous system; FRN, Future Research Needs; G.I., gastrointestinal; LCS,
low-calorie sweetener; Q, Future Research Needs question (refer to Table 2 for each FRN question).
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LCSs. It has been suggested that lead scientists should take
a more active role in communication, because they can best
put the findings in context and help clarify misunderstandings
(28).
Many stakeholder panel members also pointed to the need for
more intervention studies to look at the relation between LCSs
and other health outcomes of interest, as well as their underlying
mechanisms. The idea that cross-sectional, observational studies
are limited by reverse causality and are partially the reason for
controversy around LCSs was mentioned in several interviews.
Published systematic reviews have shared these concerns as
well (20, 21). Multiple panel members also felt that there
were enough intervention trials in the literature to justify
that LCSs can be effective for weight loss and maintenance,
but that due to public perception and some vocal opposition,
more trials may be needed. In addition, it is important to note
that the identification of evidence gaps via examination of pub-
lished studies is limited to the questions addressed; if a question
has not been examined in the literature, the need for studies to
address it may not yet be identified and should be considered
in future projects.
One recurring theme in the stakeholder interviews was the in-
adequacy of current dietary tools in accurately assessing intakes of
LCSs. There was discussion about the weaknesses of reliance on
self-reported dietary assessment measures and the need for im-
provement in nutrition research overall. Researchers on the panel
generally felt that we need better information about products con-
taining LCSs, including which sweeteners are used and in what
amounts, which is an interest shared by Miller and Perez (20).
There was also an interest expressed in collecting stronger data
on differences in global intake as well as across different racial
or ethnic groups.
Multiple stakeholders expressed an interest in identifying a
way to evaluate LCS compounds as a class. For example, when a
new LCS is developed with marketing plans, it would be advanta-
geous to have an easy way to compare it with those currently in
widespread use. This could be important, especially given the
limitation that most sweeteners have not been researched as
extensively as aspartame. Furthermore, although stakeholders
recognized that this may not be possible, there was interest in see-
ing a common measurement or endpoint for all LCSs to be able to
make a general statement about them as a group. Some endpoints
that were proposed were sweetener detection, insulin response,
perception of sweetness, or change in dietary pattern. Future re-
search would be needed to assess the accuracy of any statements
made about LCSs as a class of ingredients.
Strengths and limitations
The main advantages of this new FRN approach include the trans-
parency of the process and the inclusion of diverse perspectives on
how research needs are defined or determined for informing public
health policy. We overcame the challenges in engaging a lay audi-
ence in the panel discussions by facilitating an online discussion fo-
rum and conducting one-on-one interviews. Although we used a
novel approach to integrate evidence-mapping findings into the
FRN approach, there are several important limitations of this
approach. First, it is likely that our evidence-map database did
not include all relevant published studies due to the limitations
of our search strategies, as we only searched articles indexed on
Medline because of resource constraints. Another important lim-
itation is that, unlike systematic reviews, evidence mapping does
not provide information on the quality of published studies in-
cluded. Finally, although we made sure to select a panel with a
wide range of expertise, the limited size of our stakeholder panel
means that although our findings represent our best efforts to
identify future research priorities, it is certain that our panel did
not represent all perspectives. For example, as the project pro-
gressed, it became clear that the project would have benefited
from including a toxicologist on the stakeholder panel.
Conclusions
In summary, the stakeholder panel identified and prioritized future
research needs, with research on the role of LCSs in energy intake,
weight loss, and appetite in healthy, overweight, and diabetic popu-
lations being given the highest priority. The integration of evidence
mapping allowed our stakeholders to have a more informed con-
versation about the state of current research, and the semistruc-
tured interviews were invaluable in understanding how our
stakeholder panel arrived at the final priority-ranked list of re-
search questions. The recurrent concerns and confusions with
regard to the “safety” of LCSs underscore the importance of
communicating the science to the general public. Particularly
in the nutrition sciences, emerging research studies have the
potential to inform consumer choice.
In this FRN project, research questions that were deemed to
have the largest public health impact by the stakeholder panel
also received higher overall prioritization scores. However, it is
important to point out that behavioral and mechanistic outcomes
are currently not considered in the evidence-based health care
policy decision-making process. The breadth of our FRN ques-
tions suggests that public health nutrition policy may need to con-
sider a broader evidence base because of the complex relations
between nutrition, lifestyle, and optimal health. The future re-
search questions developed by our panel can serve as an important
resource for researchers and research funders. Furthermore, by
providing an open evidence-map database of published LCS re-
search (15) that can be used to query what has been done on
the basis of a specific research question of interest in a broad
area, we hope to contribute to the process of knowledge trans-
lation from scientific findings into health practice or policy
recommendations.
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